Chonluten
Chonluten (Lung Bioregulator)
Chonluten is a short-chain tripeptide bioregulator (Lys-Glu-Asp) derived from lung tissue, developed by the St. Petersburg Institute of Bioregulation and Gerontology. It is primarily used to support respiratory tract health, restore bronchial epithelial cell function, and is investigated for applications in chronic obstructive pulmonary disease (COPD), age-related lung decline, and recovery from respiratory infections. Chonluten belongs to the cytomax/cytogen class of peptide bioregulators originally pioneered by Vladimir Khavinson.
Mechanism of Action
Chonluten acts as a peptide bioregulator that penetrates cell nuclei and interacts directly with DNA promoter regions, specifically upregulating gene expression in bronchial and alveolar epithelial cells to restore normal protein synthesis patterns disrupted by aging or disease. It promotes differentiation and proliferation of bronchial mucosa cells, enhances mucociliary clearance, and supports surfactant production by type II pneumocytes. Additionally, it exhibits immunomodulatory properties by normalizing cytokine profiles in lung tissue and reducing pathological inflammatory signaling.
Evidence by Health Goal(4 goals)
Dosing Protocols
Morning, on empty stomach, held under tongue for 1-2 minutes before swallowing
Cycle: 10-day course, repeated 2-4 times per year
Sublingual administration is preferred over oral to bypass first-pass hepatic metabolism and improve bioavailability of this small tripeptide. Most clinical protocols from Russian research use 10-day courses.
Morning, 30 minutes before eating
Cycle: 10-day course, repeated 2-4 times per year
Oral capsule form is commercially available as Chonluten from Peptide Bioregulator suppliers. Some bioavailability loss expected compared to sublingual route but is the most common consumer format.
Safety & Side Effects
Chonluten has a favorable safety profile based on several decades of Russian clinical research with no serious adverse events reported in published studies; however, long-term randomized controlled trial data by Western regulatory standards is limited. It is not a controlled substance but is sold as a research compound or dietary supplement in most Western countries, and its regulatory status varies internationally.
Possible Side Effects
- !Mild transient fatigue during initial days of first course
- !Occasional mild headache during first 1-3 days of use
- !Rare mild gastrointestinal discomfort with oral capsule form
- !Possible transient immune activation symptoms (mild flu-like feeling) in first course
- !Local sublingual tingling or mild irritation with sublingual administration
- !Theoretical risk of hypersensitivity reaction in individuals with peptide allergies
Interactions
- -May potentiate effects of bronchodilators (e.g., salbutamol) by improving epithelial receptor sensitivity - monitor for enhanced response
- -Possible additive benefit when combined with other peptide bioregulators (e.g., Crystagen, Endoluten) - combination protocols require careful sequencing
- -May enhance mucosal immune response - use caution if on immunosuppressive therapy following organ transplant
- -Theoretical interaction with corticosteroid therapy for lung conditions - may reduce dependence on steroids over time, requiring dose adjustment monitoring
- -May complement N-acetylcysteine (NAC) and antioxidant protocols for COPD - generally considered safe combination but monitor respiratory function
Cost & Where to Buy
Typically sold in capsule form (60-count bottles) by peptide bioregulator suppliers such as Cosmic Nootropic or similar vendors. Since dosing is cycled rather than daily year-round, monthly cost is averaged across the year. Higher costs reflect pharmaceutical-grade sourcing or imported Russian products.
Search on Amazon